Dusseldorf - Delayed Quote EUR

Annovis Bio Inc (07X.DU)

Compare
4.7850
-0.1450
(-2.94%)
At close: January 10 at 7:30:13 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
30,402.3800
45,035.0110
25,511.2790
14,500.4670
5,482.7720
Operating Income
-30,402.3800
-45,035.0110
-25,511.2790
-14,500.4670
-5,482.7720
Net Non Operating Interest Income Expense
-1,598.4220
667.8980
182.7120
13.3350
47.2250
Other Income Expense
--
-11,837.2000
--
--
-26.5000
Pretax Income
-40,939.1100
-56,204.3130
-25,328.5670
-14,487.1320
-5,462.0470
Net Income Common Stockholders
-40,939.1100
-56,204.3130
-25,328.5670
-14,487.1320
-5,462.0470
Diluted NI Available to Com Stockholders
-40,939.1100
-56,204.3130
-25,328.5670
-14,487.1320
-5,462.0470
Basic EPS
-3.97
-6.23
-3.10
-1.90
-0.87
Diluted EPS
-4.22
-6.23
-3.10
-1.90
-0.87
Basic Average Shares
11,027.2960
9,023.1380
8,162.3260
7,626.2780
6,308.9610
Diluted Average Shares
11,077.2230
9,023.1380
8,162.3260
7,626.2780
6,308.9610
Total Operating Income as Reported
-30,402.3800
-45,035.0110
-25,511.2790
-14,537.2210
-6,640.2210
Total Expenses
30,402.3800
45,035.0110
25,511.2790
14,500.4670
5,482.7720
Net Income from Continuing & Discontinued Operation
-40,939.1100
-56,204.3130
-25,328.5670
-14,487.1320
-5,462.0470
Normalized Income
-32,000.8020
-44,367.1130
-25,328.5670
-14,487.1320
-5,435.5470
Interest Income
271.7060
667.8980
182.7120
13.3350
47.2250
Net Interest Income
-1,598.4220
667.8980
182.7120
13.3350
47.2250
EBIT
-30,402.3800
-45,035.0110
-25,511.2790
-14,500.4670
-5,482.7720
EBITDA
-30,402.3800
-45,035.0110
-25,511.2790
-14,500.4670
-5,482.7720
Net Income from Continuing Operation Net Minority Interest
-40,939.1100
-56,204.3130
-25,328.5670
-14,487.1320
-5,462.0470
Total Unusual Items Excluding Goodwill
-8,938.3080
-11,837.2000
--
--
-26.5000
Total Unusual Items
-8,938.3080
-11,837.2000
--
--
-26.5000
Normalized EBITDA
-21,464.0720
-33,197.8110
-25,511.2790
-14,500.4670
-5,456.2720
12/31/2020 - 12/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6XC.BE Soleno Therapeutics Inc
42.00
-2.78%
 
HSTOQ Histogen Inc.
0.0300
0.00%
 
CWBR CohBar, Inc.
0.4100
0.00%
 
PMCB PharmaCyte Biotech, Inc.
1.5200
-3.80%
 
ONCT Oncternal Therapeutics, Inc.
0.5266
-24.12%
 
KTTA Pasithea Therapeutics Corp.
2.5600
-10.49%
 
GRTX Galera Therapeutics, Inc.
0.0480
-5.88%
 
TLX Telix Pharmaceuticals Limited
14.63
-4.69%
 
CELZ Creative Medical Technology Holdings, Inc.
2.1700
-9.96%
 
ALZN Alzamend Neuro, Inc.
1.1300
-0.88%